HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share ...

Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

Live Updates Stocks on the Move Today 9:49 am Here are some notable stocks on the move today: Super Micro Computer: The ...

Stocks rebounded after last week’s slide as Treasuries stabilized after 10-year yields approached 4.5%, with traders keeping ...

That includes Big Tech, which is currently making a series of peculiar investments in a few strange companies. This has nothing to do with tech. At least on the surface … Yet, these strange ...

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.

CNBC's Jim Cramer reports on the latest news regarding Moderna. This Insane Timelapse From Hubble Will Change Your ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Nvidia's revenue is forecast to jump more than 80% to $33 billion, according to estimates compiled by LSEG, and the company ...

On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $39.77 which represents a decrease of $-2.37 or -5.62% from the prior close of $42.14. The stock opened at $42.05 and touched a ...

The news prompted a sell-off across the industry. In the US, shares in Pfizer sank more than 4% and Moderna were roughly 9% ...